Expanding the scope of PSMA-RLT: evaluating treatment in challenging mCRPC patients with poor performance status (ECOG 3)
This study indicates that PSMA-RLT is a feasible and overall well-tolerated treatment for mCRPC ECOG 3 patients with manageable toxicity profile. Despite limited survival outcomes, ECOG 3 status may be considered not to be a categorical exclusion criterion for RLT. Future prospective studies should further investigate the role of PSMA-RLT in this challenging subgroup.
Authors
- Caroline Burgard (ORCID: https://orcid.org/0000-0003-1522-8860)
- Arne Blickle (ORCID: https://orcid.org/0009-0009-2460-7249)
- Samer Ezziddin (ORCID: https://orcid.org/0000-0003-4110-3375)
- Stephan Maus (ORCID: https://orcid.org/0000-0003-1679-8080)
- Mark Bartholomä (ORCID: https://orcid.org/0000-0002-0361-2833)
- Moritz B. Bastian
- Andrea Schaefer-Schuler (ORCID: https://orcid.org/0000-0002-2439-5786)
- Florian Rosar (ORCID: https://orcid.org/0000-0002-2985-4099)
- Tilman Speicher
- Benedikt Wörl
Institutions
- Saarland University (DE)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2025-05-26
- DOI
- https://doi.org/10.1007/s00259-025-07346-4
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Universität des Saarlandes